Relay Therapeutics Inc (RLAY) Options

RLAY under $5

RLAY...$5.13...🥳Having solid News lately on this Bottom Chart...

georgie18

Member Level
Re: georgie18 post# 667203

Wednesday, December 11, 2024 2:48:21 PM

Post#
667564
of 667617
RLAY...$4.90s clearing here...🥳...https://www.globenewswire.com/news-release/2024/12/11/2995182/0/en/Relay-Therapeutics-Announces-Updated-Interim-Data-for-RLY-2608-Fulvestrant-Demonstrating-Continued-Maturation-of-Clinically-Meaningful-Progression-Free-Survival.html

georgie18

Member Level
Re: RIGATONI post# 386680

Saturday, December 07, 2024 12:12:54 PM

Post#
386697
of 386855
RLAY...$4.61...🥳... https://schrts.co/dAgygcri ...Bullish Matching Low Reversal Pattern to the Upside...Confirmation Candle coming off the Oversold Bottom...

Global licensing agreement grants Elevar Therapeutics worldwide rights to develop and commercialize lirafugratinib (RLY-4008)

Lirafugratinib is a potential best-in-class FGFR2 inhibitor that has shown differentiated efficacy in FGFR2-driven cholangiocarcinoma and demonstrated durable responses across multiple other types of FGFR2-altered solid tumors

Relay Therapeutics has potential to receive up to $500 million in upfront, regulatory and commercial milestone payments, including $75 million in upfront and regulatory milestones, plus up to double digit royalties on global sales

CAMBRIDGE, Mass. and FORT LEE, N.J., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, and Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and fully integrated biopharmaceutical company dedicated to elevating treatment outcomes for patients who have limited or inadequate therapeutic options, today announced an exclusive global licensing agreement for lirafugratinib (RLY-4008). Lirafugratinib is a selective oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2) that is being developed for patients with FGFR2-driven cholangiocarcinoma (CCA) and other FGFR2-altered solid tumors. The announcement of the partnership follows Relay’s recent positive FDA interaction and previously reported differentiated data in cholangiocarcinoma and data across other solid tumors.

RLAY...$4.90s clearing here...🥳...https://www.globenewswire.com/news-release/2024/12/11/2995182/0/en/Relay-Therapeutics-Announces-Updated-Interim-Data-for-RLY-2608-Fulvestrant-Demonstrating-Continued-Maturation-of-Clinically-Meaningful-Progression-Free-Survival.html

georgie18

Member Level
Re: RIGATONI post# 386680

Saturday, December 07, 2024 12:12:54 PM

Post#
386697
of 386855
RLAY...$4.61...🥳... https://schrts.co/dAgygcri ...Bullish Matching Low Reversal Pattern to the Upside...Confirmation Candle coming off the Oversold Bottom...

Global licensing agreement grants Elevar Therapeutics worldwide rights to develop and commercialize lirafugratinib (RLY-4008)

Lirafugratinib is a potential best-in-class FGFR2 inhibitor that has shown differentiated efficacy in FGFR2-driven cholangiocarcinoma and demonstrated durable responses across multiple other types of FGFR2-altered solid tumors

Relay Therapeutics has potential to receive up to $500 million in upfront, regulatory and commercial milestone payments, including $75 million in upfront and regulatory milestones, plus up to double digit royalties on global sales

CAMBRIDGE, Mass. and FORT LEE, N.J., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, and Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and fully integrated biopharmaceutical company dedicated to elevating treatment outcomes for patients who have limited or inadequate therapeutic options, today announced an exclusive global licensing agreement for lirafugratinib (RLY-4008). Lirafugratinib is a selective oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2) that is being developed for patients with FGFR2-driven cholangiocarcinoma (CCA) and other FGFR2-altered solid tumors. The announcement of the partnership follows Relay’s recent positive FDA interaction and previously reported differentiated data in cholangiocarcinoma and data across other solid tumors.

RLAY...................https://stockcharts.com/h-sc/ui?s=RLAY&p=W&b=5&g=0&id=p86431144783

RLAY...$4.61...🥳... https://schrts.co/dAgygcri ...Bullish Matching Low Reversal Pattern to the Upside...Confirmation Candle coming off the Oversold Bottom...

Global licensing agreement grants Elevar Therapeutics worldwide rights to develop and commercialize lirafugratinib (RLY-4008)

Lirafugratinib is a potential best-in-class FGFR2 inhibitor that has shown differentiated efficacy in FGFR2-driven cholangiocarcinoma and demonstrated durable responses across multiple other types of FGFR2-altered solid tumors

Relay Therapeutics has potential to receive up to $500 million in upfront, regulatory and commercial milestone payments, including $75 million in upfront and regulatory milestones, plus up to double digit royalties on global sales

CAMBRIDGE, Mass. and FORT LEE, N.J., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, and Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and fully integrated biopharmaceutical company dedicated to elevating treatment outcomes for patients who have limited or inadequate therapeutic options, today announced an exclusive global licensing agreement for lirafugratinib (RLY-4008). Lirafugratinib is a selective oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2) that is being developed for patients with FGFR2-driven cholangiocarcinoma (CCA) and other FGFR2-altered solid tumors. The announcement of the partnership follows Relay’s recent positive FDA interaction and previously reported differentiated data in cholangiocarcinoma and data across other solid tumors.

RLAY under $10

RLAY under $10

Using AI to find the next blockbuster drug
This week, AI chipmaker Nvidia placed their bet — investing $50M into AI drug discovery platform Recursion Pharmaceuticals (NASDAQ:RXRX) — sending its stock up 78%.



Drugmakers are already benefiting from using AI to discover new drugs. And in the process, AI is speeding up and reducing the cost of the long and expensive drug development process.
Between 2015 and 2022, the cumulative investment in AI drug development has risen from under $1B to $24.6B.
In the next decade, Morgan Stanley expects AI will help develop an additional 50 drugs with an extra $50B in sales.
Following Nvidia’s investment, other AI drug discovery platforms rose on the news, including Exscientia (NASDAQ:EXAI), AbCellera Biologics (NASDAQ:ABCL) and Relay Therapeutics (NASDAQ:RLAY).
Recursion has five drugs, and Exscientia has three drugs discovered with AI, which are already in human trials. And within the startup sector, AI drug discovery has quickly become one of the hottest markets for investment.